The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
SRM Medical College Hospital and Research Centre hosts undergraduate research expo highlighting innovation, interdisciplinary collaboration, and the role of artificial intelligence
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Subscribe To Our Newsletter & Stay Updated
